GPSM2

Across TCGA pan-cancer cohorts, GPSM2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GPSM2 data layer compared with 31 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher GPSM2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GPSM2 expression acts as an unfavorable survival marker, although some lineages such as COAD and GBM show a favorable association.

COAD, GBM, and CCRCC are the cancer types where GPSM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Tertile	All	1.000	0.792	.025	24	view →
GBM	DFS	Median	All	0.452	0.295	.005	9	view →
CCRCC	OS	Median	II,III,IV	0.150	0.859	.038	6	view →
LSCC	OS	Median	II,III,IV	0.933	0.681	.024	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GPSM2–COAD (DFS)

Open the COAD breakdown →